These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 18413834)

  • 1. Sunitinib for treatment of advanced renal cell cancer: primary tumor response.
    van der Veldt AA; Meijerink MR; van den Eertwegh AJ; Bex A; de Gast G; Haanen JB; Boven E
    Clin Cancer Res; 2008 Apr; 14(8):2431-6. PubMed ID: 18413834
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Computed tomography characteristics of unresectable primary renal cell carcinoma treated with neoadjuvant sunitinib.
    Salem ME; Shah SN; Elson P; Garcia JA; Wood LS; Medsinge A; Campbell S; Dreicer R; Rini BI
    Clin Genitourin Cancer; 2014 Apr; 12(2):117-23. PubMed ID: 24126239
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Presurgical sunitinib reduces tumor size and may facilitate partial nephrectomy in patients with renal cell carcinoma.
    Lane BR; Derweesh IH; Kim HL; O'Malley R; Klink J; Ercole CE; Palazzi KL; Thomas AA; Rini BI; Campbell SC
    Urol Oncol; 2015 Mar; 33(3):112.e15-21. PubMed ID: 25532471
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of sunitinib on primary renal cell carcinoma and facilitation of subsequent surgery.
    Rini BI; Garcia J; Elson P; Wood L; Shah S; Stephenson A; Salem M; Gong M; Fergany A; Rabets J; Kaouk J; Krishnamurthi V; Klein E; Dreicer R; Campbell S
    J Urol; 2012 May; 187(5):1548-54. PubMed ID: 22425095
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Neoadjuvant therapy for renal cancer].
    Thibault F; Rixe O; Meric JB; Renard-Penna R; Boostan H; Mozer P; Comperat E; Richard F; Bitker MO
    Prog Urol; 2008 Apr; 18(4):256-8. PubMed ID: 18501308
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase II study of presurgical sunitinib in patients with metastatic clear-cell renal carcinoma and the primary tumor in situ.
    Bex A; Blank C; Meinhardt W; van Tinteren H; Horenblas S; Haanen J
    Urology; 2011 Oct; 78(4):832-7. PubMed ID: 21802123
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dramatic reduction in tumor burden with neoadjuvant sunitinib prior to bilateral nephron-sparing surgery.
    Gorin MA; Ekwenna O; Soloway MS; Ciancio G
    Urology; 2012 Feb; 79(2):e11. PubMed ID: 21676439
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Response of the primary tumor to neoadjuvant sunitinib in patients with advanced renal cell carcinoma.
    Thomas AA; Rini BI; Lane BR; Garcia J; Dreicer R; Klein EA; Novick AC; Campbell SC
    J Urol; 2009 Feb; 181(2):518-23; discussion 523. PubMed ID: 19100579
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sunitinib in patients with metastatic renal cell carcinoma.
    Motzer RJ; Rini BI; Bukowski RM; Curti BD; George DJ; Hudes GR; Redman BG; Margolin KA; Merchan JR; Wilding G; Ginsberg MS; Bacik J; Kim ST; Baum CM; Michaelson MD
    JAMA; 2006 Jun; 295(21):2516-24. PubMed ID: 16757724
    [TBL] [Abstract][Full Text] [Related]  

  • 10. First-Line sunitinib in patients with renal cell carcinoma (RCC) in von Hippel-Lindau (VHL) disease: clinical outcome and patterns of radiological response.
    Roma A; Maruzzo M; Basso U; Brunello A; Zamarchi R; Bezzon E; Pomerri F; Zovato S; Opocher G; Zagonel V
    Fam Cancer; 2015 Jun; 14(2):309-16. PubMed ID: 25391617
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early experience with targeted therapy and dendritic cell vaccine in metastatic renal cell carcinoma after nephrectomy.
    Dall'Oglio MF; Sousa-Canavez JM; Tanno FY; Tiseo BC; Crippa A; Dos Reis ST; Leite KR; Srougi M
    Int Braz J Urol; 2011; 37(2):180-5; discussion 185-6. PubMed ID: 21557834
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Advanced sarcomatoid renal cell carcinoma effectively treated with sunitinib: report of a case].
    Tsuchiyama K; Ito H; Ishida H; Itoh H; Yokoyama O
    Hinyokika Kiyo; 2011 Nov; 57(11):615-8. PubMed ID: 22166824
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neoadjuvant sunitinib facilitates nephron-sparing surgery and avoids long-term dialysis in a patient with metachronous contralateral renal cell carcinoma.
    Ansari J; Doherty A; McCafferty I; Wallace M; Deshmukh N; Porfiri E
    Clin Genitourin Cancer; 2009 Aug; 7(2):E39-41. PubMed ID: 19692322
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prolonged complete responses and near-complete responses to sunitinib in metastatic renal cell carcinoma.
    Heng DY; Rini BI; Garcia J; Wood L; Bukowski RM
    Clin Genitourin Cancer; 2007 Dec; 5(7):446-51. PubMed ID: 18272027
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [NEOADJUVANT TARGET THERAPY IN A RENAL-CELL CANCER].
    Stakhovskiy EO; Voylenko OA; Stakhovskiy OE; Vitruk YV; Vukalovych PS; Kononenko OA
    Klin Khir; 2015 Dec; (12):41-3. PubMed ID: 27025031
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma.
    Goodman VL; Rock EP; Dagher R; Ramchandani RP; Abraham S; Gobburu JV; Booth BP; Verbois SL; Morse DE; Liang CY; Chidambaram N; Jiang JX; Tang S; Mahjoob K; Justice R; Pazdur R
    Clin Cancer Res; 2007 Mar; 13(5):1367-73. PubMed ID: 17332278
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vascular Tumor Burden as a New Quantitative CT Biomarker for Predicting Metastatic RCC Response to Antiangiogenic Therapy.
    Smith AD; Zhang X; Bryan J; Souza F; Roda M; Sirous R; Zhang H; Vasanji A; Griswold M
    Radiology; 2016 Nov; 281(2):484-498. PubMed ID: 27603788
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sunitinib treatment in patients with severe renal function impairment: a report of four cases by the Hellenic Cooperative Oncology Group.
    Lainakis G; Bamias A; Psimenou E; Fountzilas G; Dimopoulos MA
    Clin Nephrol; 2009 Jul; 72(1):73-8. PubMed ID: 19640391
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Feasibility and efficacy of neoadjuvant sunitinib before nephron-sparing surgery.
    Silberstein JL; Millard F; Mehrazin R; Kopp R; Bazzi W; DiBlasio CJ; Patterson AL; Downs TM; Yunus F; Kane CJ; Derweesh IH
    BJU Int; 2010 Nov; 106(9):1270-6. PubMed ID: 20394613
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antitumor effects of sunitinib or sorafenib in patients with metastatic renal cell carcinoma who received prior antiangiogenic therapy.
    Tamaskar I; Garcia JA; Elson P; Wood L; Mekhail T; Dreicer R; Rini BI; Bukowski RM
    J Urol; 2008 Jan; 179(1):81-6; discussion 86. PubMed ID: 17997441
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.